Stepan SEC Filings

Stepan Co. director F. Quinn Stepan Jr. reported transfers and deferred-compensation share units resulting in increased reported holdings. On 08/12/2025 he received 20,676 shares from his mother's estate and a trust received 2,448 shares from the same estate. The filing notes he disclaims beneficial ownership of certain shares except to the extent of any pecuniary interest and that he serves as executor of his mother's estate.

The report also shows participation in the Management Incentive Plan where 63,404.923 share units are held directly and 43,166.868 share units indirectly; these units convert one-for-one into common stock and are generally payable at end of employment. The transactions are transfers and deferred-compensation allocations rather than open-market purchases or sales.

Director Corning F. Painter purchased 2,433 shares of Stepan Co common stock at $49.09 on 08/08/2025, increasing his direct holding to 2,433 shares. The Form 4 discloses this as a direct acquisition by a board member and records the transaction on the companys insider reporting form.

Joaquin Delgado, a director of Stepan Co. (SCL), acquired 2,500 shares of common stock on 05/12/2025 at a reported price of $54.262 per share, increasing his beneficial ownership to 16,071 shares. The Form 4 discloses only a non-derivative purchase and shows no derivative transactions or dispositions.

Stepan Company (SCL) reported equity awards granted to Ruben D. Velasquez, who is the company’s Vice President and Chief Financial Officer. On 08/08/2025 he acquired 2,037 performance shares, 4,074 restricted stock units (RSUs) and 5,714 stock appreciation rights (SARs). The SARs show a stated exercise/conversion price of $49.09. Each performance share and each RSU represents a contingent right to receive one share of common stock, and the reported acquisition amounts are recorded at a price of $0.

The performance shares vest upon certification of Stepan achieving specified performance goals for the period ending December 31, 2027. The RSUs and SARs become exercisable beginning 08/08/2026; RSUs vest ratably over three years from that date, and the SARs expire on 08/08/2035. All reported holdings are shown as direct beneficial ownership.

Stepan Co. (SCL) Form 4 filed 08/06/25 details insider activity by Director F. Quinn Stepan Jr. on 08/04-05/25.

• Sales: 6,300 shares at $49.962 and 3,700 shares at $50.489 (≈10,000 total; ≈$500k gross).
• Gift: 3,000 shares transferred to joint tenancy with spouse at no cost (Code G).
• Other: 0.615 shares withheld for taxes (Code F) and 2.281 deferred share units converted to stock (Code G/A).

Post-trade direct ownership drops to 159,423 shares, down roughly 6%, while indirect interests total ≈429 k shares across family LLCs, trusts, ESOPs and estates. The director also holds 63,405 deferred share units plus 43,167 units in his father’s deferred plan.

No Rule 10b5-1 trading plan box was marked, suggesting discretionary transactions. Given the company’s ~22 m share float, the 10 k-share sale is immaterial to liquidity but may be watched as a sentiment signal.

Stepan Company (NYSE: SCL) filed its Q2-25 Form 10-Q. Net sales rose 6.9% YoY to $594.7 million, driven by 8.3% growth in Surfactants and 1.9% in Polymers; Specialty Products advanced 21.5%. Gross profit improved 3.4% to $71.9 million, but operating income slipped 3.8% to $18.0 million as selling and R&D costs increased 6.0%. Higher interest expense (-106% YoY) cut pre-tax earnings 20% to $13.8 million; however, a sharply lower effective tax rate (17.7% vs. 44.7%) lifted net income 19% to $11.3 million, or $0.50 diluted EPS.

For the six-month period, revenue gained 7.2% to $1.19 billion and operating income rose 19% to $46.3 million. Net income reached $31.1 million (+32.6%), translating to $1.36 EPS.

Segment detail (Q2): Polymers profit jumped 26% to $17.2 million on higher volume and price/mix, offsetting declines in Surfactants (-22%) and Specialty Products (-28%). Corporate expense fell 8%.

Balance sheet: Cash fell to $88.9 million (-$10.8 million YTD) as operating cash flow weakened to $18.1 million from $71.1 million. Capex remained elevated at $58.3 million. Total debt increased 5.3% to $658 million after issuing $75 million of 6.17% senior notes; net leverage stands near 1.1× EBITDA. Equity improved to $1.24 billion, aided by a $57 million favorable FX translation adjustment that reduced AOCI.

Other highlights: • Assets of the Philippine surfactant plant ($8.7 million) classified as held for sale.
• Environmental liabilities accrued at $19.5 million (low end of $19.5–$44.9 million range).
• New U.S. tax act (enacted 7-4-25) not yet reflected; management expects no material 2025 impact.

Outlook: Management continues to invest in capacity (capex $58 million YTD) while navigating higher financing costs and mixed segment margins. Sale of the Philippine site and working-capital normalization are expected to support liquidity in 2H-25.